Your browser is no longer supported. Please, upgrade your browser.
AVRO AVROBIO, Inc. daily Stock Chart
AVRO [NASD]
AVROBIO, Inc.
Index- P/E- EPS (ttm)-2.72 Insider Own11.80% Shs Outstand33.67M Perf Week-2.03%
Market Cap629.55M Forward P/E- EPS next Y-3.27 Insider Trans-2.05% Shs Float29.34M Perf Month-22.73%
Income-81.80M PEG- EPS next Q-0.76 Inst Own84.30% Short Float6.66% Perf Quarter24.54%
Sales- P/S- EPS this Y-30.30% Inst Trans20.71% Short Ratio5.51 Perf Half Y-15.44%
Book/sh7.62 P/B2.28 EPS next Y-4.10% ROA-41.50% Target Price- Perf Year20.23%
Cash/sh7.13 P/C2.44 EPS next 5Y- ROE-44.10% 52W Range9.76 - 29.32 Perf YTD-13.51%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.62% Beta-
Dividend %- Quick Ratio20.80 Sales past 5Y- Gross Margin- 52W Low78.38% ATR1.12
Employees112 Current Ratio20.80 Sales Q/Q- Oper. Margin- RSI (14)38.76 Volatility4.14% 6.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.80% Profit Margin- Rel Volume0.45 Prev Close17.51
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume354.67K Price17.41
Recom1.90 SMA20-11.11% SMA50-6.06% SMA200-0.87% Volume160,234 Change-0.57%
Mar-31-20Downgrade H.C. Wainwright Buy → Neutral $13
Jun-27-19Initiated Mizuho Buy $28
Apr-05-19Initiated Janney Buy
Oct-10-18Initiated Guggenheim Buy
Oct-02-18Reiterated H.C. Wainwright Buy $47 → $40
Sep-17-18Initiated H.C. Wainwright Buy $47
Jul-16-18Initiated Wells Fargo Outperform $40
Jul-16-18Initiated Wedbush Outperform $38
Jul-16-18Initiated Morgan Stanley Overweight $37
Jul-08-20 07:00AM  
Jul-06-20 07:00AM  
Jun-29-20 07:00AM  
Jun-24-20 04:16PM  
May-14-20 07:00AM  
May-13-20 07:00AM  
May-09-20 08:36AM  
May-08-20 08:42AM  
May-07-20 07:00AM  
May-06-20 04:05PM  
07:00AM  
May-05-20 07:00AM  
May-04-20 07:00AM  
Apr-14-20 08:58AM  
Apr-12-20 02:26PM  
02:26PM  
Apr-03-20 07:00AM  
Mar-30-20 04:30PM  
02:10PM  
Mar-26-20 07:00AM  
Mar-25-20 07:47PM  
07:00AM  
Mar-19-20 12:00PM  
Mar-17-20 05:58PM  
01:57PM  
12:53PM  
12:25PM  
Mar-16-20 07:00AM  
Mar-09-20 07:00AM  
Mar-05-20 07:00AM  
Feb-24-20 07:00AM  
Feb-18-20 04:01PM  
Feb-12-20 10:08PM  
04:01PM  
Feb-11-20 07:23AM  
Feb-10-20 04:01PM  
Feb-06-20 07:00AM  
Feb-04-20 07:00AM  
Jan-14-20 07:00AM  
Jan-09-20 04:00PM  
Dec-19-19 08:00AM  
Dec-16-19 08:00AM  
Dec-14-19 07:47PM  
Nov-07-19 07:00AM  
Nov-06-19 02:31PM  
Oct-24-19 07:00AM  
Oct-22-19 07:00AM  
Oct-16-19 06:02AM  
Oct-08-19 07:00AM  
Oct-03-19 08:00AM  
Sep-27-19 09:00AM  
Sep-11-19 10:22AM  
Aug-29-19 07:00AM  
Aug-16-19 08:30AM  
Aug-12-19 05:36PM  
Aug-08-19 07:00AM  
04:02AM  
Aug-06-19 08:00AM  
Jul-29-19 08:08AM  
Jul-26-19 07:51AM  
Jul-19-19 04:01PM  
Jul-18-19 05:57AM  
Jul-17-19 04:26PM  
12:35PM  
Jul-16-19 09:58PM  
04:01PM  
Jul-15-19 04:28PM  
07:00AM  
May-13-19 07:00AM  
May-12-19 06:43PM  
Apr-29-19 07:00AM  
Apr-26-19 04:00PM  
Mar-25-19 07:00AM  
Mar-05-19 07:00AM  
Feb-06-19 09:00AM  
Feb-05-19 02:48PM  
Feb-01-19 07:00AM  
Jan-18-19 07:43AM  
07:00AM  
Jan-17-19 07:00AM  
Jan-07-19 07:06AM  
Dec-21-18 10:00AM  
12:41AM  
Dec-19-18 07:00AM  
Dec-18-18 07:05AM  
07:00AM  
Nov-28-18 01:05PM  
Nov-21-18 07:35AM  
Nov-13-18 08:00AM  
Oct-04-18 04:01PM  
Oct-01-18 07:01AM  
07:00AM  
Aug-09-18 08:00AM  
Aug-08-18 08:00AM  
Jul-16-18 10:52AM  
Jun-27-18 08:00AM  
Jun-25-18 04:30PM  
Jun-22-18 08:13PM  
Jun-21-18 11:41AM  
Jun-20-18 10:01PM  
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MACKAY GEOFFREYSee RemarksFeb 12Sale29.071,40040,692345,123Feb 14 07:16 PM
PAIGE CHRISTOPHERDirectorFeb 11Sale28.0015,000420,000252,512Feb 11 09:26 PM
MACKAY GEOFFREYSee RemarksFeb 11Sale27.5763,0001,737,081346,523Feb 11 09:23 PM
PAIGE CHRISTOPHERDirectorJan 28Sale23.0010,000230,000267,512Jan 30 04:10 PM